Creative Medical Technology Holdings, Inc. CELZ
1.03
0.06
6.19%
as of 25 Sep
- Market cap
- $6.4M
- P/E
- 0.0×
Follow CELZ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (77.91%) | (81.19%) | (86.47%) | (98.14%) |
+8 more TTM periods Free account |
|
| (73.30%) | (77.93%) | (82.81%) | (93.58%) | ||
ROIC |
0.00% | (1,304.33%) | (1,213.03%) | (1,758.41%) | |
Return on Tangible Assets |
(72.60%) | (100.19%) | (84.27%) | (115.75%) | |
Average Days of Receivables |
— | — | 0.00 | — | |
Free Cash Flow per Share |
(1.59) | (1.51) | (2.46) | (2.27) | |
Free Cash Flow |
(5.90) | (5.59) | (5.86) | (5.87) | |
Piotroski F-Score |
— | — | 2.00 | — | |
| Other line items | |||||
Cash ROIC |
(33.69%) | (46.64%) | (39.75%) | (53.51%) | |
Accounts Receivable Turnover |
— | — | 0.00 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.02 | 0.00 | |
Inventory Turnover |
— | — | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 14,970.53 | 0.00 | |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 13,293.53% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 22,138.24% | 0.00% | |
Share Based Compensation of Revenue |
— | — | 20.59% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.98 | 0.97 | 0.98 | 0.98 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.00 | |
Operating CF per Share |
(1.59) | (1.51) | (2.46) | (2.27) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | (35,264.71%) | 0.00% |
Columns are period end dates